argenx SE (ARGX.BR)
EUR 575.6
(1.34%)
EUR 575.6
(1.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.34 Billion EUR | 21.95% |
| 2022 | 1.1 Billion USD | 30.14% |
| 2021 | 846.02 Million USD | 50.6% |
| 2020 | 561.76 Million EUR | 101.06% |
| 2019 | 279.4 Million EUR | 136.38% |
| 2018 | 118.2 Million EUR | 66.02% |
| 2017 | 71.19 Million EUR | 87.38% |
| 2016 | 37.99 Million EUR | 54.75% |
| 2015 | 24.55 Million EUR | 39.27% |
| 2014 | 17.63 Million EUR | 43.36% |
| 2013 | 12.29 Million EUR | -20.53% |
| 2012 | 15.47 Million EUR | 150.53% |
| 2011 | 6.17 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 469.19 Million EUR | 108.32% |
| 2024 Q1 | 449.45 Million USD | 8.97% |
| 2023 Q3 | 373.63 Million USD | 7.68% |
| 2023 Q1 | 304.28 Million USD | 10.6% |
| 2023 Q2 | 347 Million USD | 14.04% |
| 2023 FY | 1.34 Billion EUR | 21.95% |
| 2023 Q4 | 504.19 Million USD | 34.94% |
| 2022 FY | 1.1 Billion USD | 30.14% |
| 2022 Q3 | 336.35 Million USD | 37.44% |
| 2022 Q4 | 275.12 Million USD | -18.2% |
| 2022 Q1 | 244.76 Million USD | -8.7% |
| 2022 Q2 | 244.72 Million USD | -0.02% |
| 2021 Q1 | 169.32 Million EUR | -29.33% |
| 2021 FY | 846.02 Million USD | 50.6% |
| 2021 Q2 | 217.1 Million USD | 28.22% |
| 2021 Q3 | 213.81 Million USD | -1.52% |
| 2021 Q4 | 268.08 Million USD | 25.38% |
| 2020 Q4 | 239.6 Million EUR | 0.0% |
| 2020 FY | 561.76 Million EUR | 101.06% |
| 2020 Q2 | 231.81 Million EUR | 0.0% |
| 2019 Q1 | 47.72 Million EUR | 18.96% |
| 2019 FY | 279.4 Million EUR | 136.38% |
| 2019 Q4 | 93.81 Million EUR | 62.81% |
| 2019 Q3 | 57.62 Million EUR | -9.55% |
| 2019 Q2 | 63.7 Million EUR | 33.49% |
| 2018 Q2 | 25.75 Million EUR | 5.94% |
| 2018 Q3 | 28.02 Million EUR | 8.83% |
| 2018 FY | 118.2 Million EUR | 66.02% |
| 2018 Q1 | 24.3 Million EUR | 10.51% |
| 2018 Q4 | 40.11 Million EUR | 43.12% |
| 2017 Q1 | 16.08 Million EUR | 33.0% |
| 2017 Q2 | 17.31 Million EUR | 7.63% |
| 2017 Q4 | 21.99 Million EUR | 39.24% |
| 2017 Q3 | 15.79 Million EUR | -8.77% |
| 2017 FY | 71.19 Million EUR | 87.38% |
| 2016 Q3 | 11.43 Million EUR | 33.09% |
| 2016 Q1 | 5.88 Million EUR | -20.76% |
| 2016 FY | 37.99 Million EUR | 54.75% |
| 2016 Q2 | 8.58 Million EUR | 46.01% |
| 2016 Q4 | 12.09 Million EUR | 5.82% |
| 2015 Q2 | 6.35 Million EUR | 32.24% |
| 2015 FY | 24.55 Million EUR | 39.27% |
| 2015 Q4 | 7.42 Million EUR | 24.5% |
| 2015 Q3 | 5.96 Million EUR | -6.25% |
| 2015 Q1 | 4.8 Million EUR | -25.43% |
| 2014 Q2 | 4.04 Million EUR | 31.48% |
| 2014 Q3 | 4.05 Million EUR | 0.37% |
| 2014 Q4 | 6.44 Million EUR | 58.85% |
| 2014 FY | 17.63 Million EUR | 43.36% |
| 2014 Q1 | 3.07 Million EUR | 1.17% |
| 2013 Q2 | 4.53 Million EUR | 53.45% |
| 2013 Q3 | 1.77 Million EUR | -60.89% |
| 2013 Q4 | 3.04 Million EUR | 71.6% |
| 2013 Q1 | 2.95 Million EUR | 0.0% |
| 2013 FY | 12.29 Million EUR | -20.53% |
| 2012 FY | 15.47 Million EUR | 150.53% |
| 2011 FY | 6.17 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nicox S.A. | -11.5 Million EUR | 11772.174% |
| European Medical Solutions | 13.64 Million EUR | -9738.427% |
| FERMENTALG | 12.34 Million EUR | -10776.945% |
| BioSenic S.A. | 7.58 Million EUR | -17606.055% |
| Celyad Oncology SA | 8.49 Million EUR | -15714.489% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | -7364.558% |
| Onward Medical N.V. | 20.64 Million EUR | -6403.512% |
| Oxurion NV | 12.21 Million EUR | -10892.714% |
| PHAXIAM Therapeutics S.A. | 24.98 Million EUR | -5273.61% |
| Financière de Tubize SA | 114.38 Thousand EUR | -1173658.078% |
| UCB SA | 2.94 Billion EUR | 54.347% |